# Nucleic Acid Drugs Sector

Canonical URL: https://biopharmsignal.com/sector/nucleic-acid-drugs

Nucleic Acid Drugs includes companies developing RNA, DNA, antisense, siRNA, mRNA, or related therapeutic approaches. This category is useful for tracking businesses whose core assets rely on sequence-based medicines rather than traditional small molecules or antibodies.

Companies currently grouped under Nucleic Acid Drugs: 27

## Recent Sector News

- 2026-07-20 07:00 EST — GSK — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — GSK — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:00 EST — ALNY — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-15 13:40 EST — GSK — [GSK completes acquisition of Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-nuvalent-inc-c44954f4) — Source: GSK plc
- 2026-07-15 12:00 EST — ALNY — [Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurologi](https://biopharmsignal.com/news/ALNY/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-showcasing-p-508fc61d) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-13 07:00 EST — GSK — [Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer](https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi--18610cf7) — Source: GSK plc
- 2026-07-10 11:00 EST — GSK — [GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-b379a2b1) — Source: GSK plc
- 2026-07-09 18:25 EST — ALNY — [Alnylam to Webcast Presentations at Upcoming Investor Conferences](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-presentations-at-upcoming-investor-conferences-50fb6676) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:25 EST — ALNY — [New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutris](https://biopharmsignal.com/news/ALNY/new-data-analyses-presented-at-heart-failure-2026-demonstrate-robust-and-consist-d10768e9) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam Issues 2025 Corporate Responsibility Report](https://biopharmsignal.com/news/ALNY/alnylam-issues-2025-corporate-responsibility-report-62023cfe) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics](https://biopharmsignal.com/news/ALNY/alnylam-and-inceptive-form-strategic-ai-collaboration-to-accelerate-the-discover-3d8b2b06) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam to Host Tenth “RNAi Roundtable” Webcast Series](https://biopharmsignal.com/news/ALNY/alnylam-to-host-tenth-rnai-roundtable-webcast-series-3988e623) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 10:00 EST — GSK — [Roy Jakobs to join GSK Board as Non-Executive Director](https://biopharmsignal.com/news/GSK/roy-jakobs-to-join-gsk-board-as-non-executive-director-560f2019) — Source: GSK plc
- 2026-07-09 03:04 EST — GRNA — [GreenLight Biosciences 2026](https://biopharmsignal.com/news/GRNA/greenlight-biosciences-2026-129baf81) — Source: GreenLight Biosciences
- 2026-07-09 03:04 EST — GRNA — [GreenLight Biosciences 2026](https://biopharmsignal.com/news/GRNA/greenlight-biosciences-2026-ec9050fc) — Source: GreenLight Biosciences
- 2026-07-09 03:04 EST — GRNA — [GreenLight Biosciences 2026](https://biopharmsignal.com/news/GRNA/greenlight-biosciences-2026-b288247c) — Source: GreenLight Biosciences
- 2026-07-09 03:04 EST — GRNA — [GreenLight Biosciences 2026](https://biopharmsignal.com/news/GRNA/greenlight-biosciences-2026-655767c6) — Source: GreenLight Biosciences
- 2026-06-30 20:25 EST — SRPT — [Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SRPT/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--c021b8ab) — Source: Sarepta Therapeutics
- 2026-06-30 12:30 EST — SRPT — [Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®](https://biopharmsignal.com/news/SRPT/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-40aea7f9) — Source: Sarepta Therapeutics
- 2026-06-26 12:45 EST — MDNA — [Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights](https://biopharmsignal.com/news/MDNA/medicenna-therapeutics-reports-fiscal-year-2026-financial-results-and-operationa-270c22c3) — Source: Medicenna Therapeutics Corp.

## Companies

- [ALNY](https://biopharmsignal.com/company/ALNY) — Alnylam Pharmaceuticals, Inc.
- [APDN](https://biopharmsignal.com/company/APDN) — Applied DNA SciencesDNA
- [ATYR](https://biopharmsignal.com/company/ATYR) — aTyr Pharma
- [RNA](https://biopharmsignal.com/company/RNA) — Avidity Biosciences
- [BNTX](https://biopharmsignal.com/company/BNTX) — BioNTech
- [RNAC](https://biopharmsignal.com/company/RNAC) — Cartesian Therapeutics
- [LLY](https://biopharmsignal.com/company/LLY) — Eli Lilly
- [ETAO](https://biopharmsignal.com/company/ETAO) — Etao International Group
- [GILD](https://biopharmsignal.com/company/GILD) — Gilead Sciences
- [DNA](https://biopharmsignal.com/company/DNA) — Ginkgo Bioworks Holdings, Inc.
- [GRNA](https://biopharmsignal.com/company/GRNA) — GreenLight Biosciences
- [GSK](https://biopharmsignal.com/company/GSK) — GSK plc
- [IONS](https://biopharmsignal.com/company/IONS) — Ionis Pharmaceuticals, Inc.
- [JNJ](https://biopharmsignal.com/company/JNJ) — Johnson & Johnson
- [KYTX](https://biopharmsignal.com/company/KYTX) — Kyverna Therapeutics
- [MDNA](https://biopharmsignal.com/company/MDNA) — Medicenna Therapeutics Corp.
- [MTD](https://biopharmsignal.com/company/MTD) — Mettler-Toledo International, Inc.
- [MRNA](https://biopharmsignal.com/company/MRNA) — Moderna, Inc.
- [NTRA](https://biopharmsignal.com/company/NTRA) — Natera
- [NVS](https://biopharmsignal.com/company/NVS) — Novartis AG
- [ONCT](https://biopharmsignal.com/company/ONCT) — Oncternal Therapeutics
- [PFE](https://biopharmsignal.com/company/PFE) — Pfizer, Inc.
- [SRPT](https://biopharmsignal.com/company/SRPT) — Sarepta Therapeutics
- [SELB](https://biopharmsignal.com/company/SELB) — Selecta
- [SLN](https://biopharmsignal.com/company/SLN) — Silence Therapeutics
- [RNAZ](https://biopharmsignal.com/company/RNAZ) — TransCode Therapeutics, Inc.
- [VRNA](https://biopharmsignal.com/company/VRNA) — Verona Pharma